Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$3.82M Buy
10,552
+2,692
+34% +$922K 1.68% 12
2026
Q1
$2.77M Sell
7,860
-4,763
-38% -$1.7M 1.42% 14
2025
Q4
$4.13M Buy
12,623
+948
+8% +$301K 2.05% 11
2025
Q3
$3.29M Buy
11,675
+1,032
+10% +$299K 1.79% 12
2025
Q2
$2.97M Sell
10,643
-2,508
-19% -$711K 1.91% 8
2025
Q1
$4.1M Buy
13,151
+2,301
+21% +$679K 2.77% 4
2024
Q4
$2.81M Sell
10,850
-712
-6% -$211K 1.51% 8
2024
Q3
$3.73M Buy
11,562
+1,877
+19% +$614K 2.15% 3
2024
Q2
$3.03M Buy
9,685
+188
+2% +$55.2K 1.72% 8
2024
Q1
$2.7M Buy
9,497
+6,620
+230% +$1.94M 1.51% 8
2023
Q4
$829K Buy
2,877
+466
+19% +$127K 0.58% 32
2023
Q3
$648K Buy
2,411
+480
+25% +$120K 0.6% 29
2023
Q2
$429K Sell
1,931
-266
-12% -$61.7K 0.39% 55
2023
Q1
$531K Buy
+2,197
New +$539K 0.47% 48
2022
Q4
Sell
-780
Closed -$176K 645
2022
Q3
$176K Buy
780
+420
+117% +$102K 0.17% 130
2022
Q2
$6.1K Sell
360
-501
-58% -$123K ﹤0.01% 513
2022
Q1
$208K Sell
861
-225,908
-100% -$51.9M 0.13% 156
2021
Q4
$1.01K Buy
+226,769
New +$47.9M 0.01% 391
2021
Q2
$185K Buy
+758
New +$186K 0.08% 218

Other funds holding AMGN

Castleview Partners's AMGN Position: Q2 2026 in Review

Castleview Partners increased its Amgen (AMGN) stake by 34% in Q2 2026, buying an estimated $922K and bringing the position to 10,552 shares worth $3.82M. The position accounts for 1.68% of the portfolio, ranked #12.

Castleview Partners first reported a position in AMGN in Q2 2021 and has held it in 19 quarters since. The position peaked at $4.13M in Q4 2025. 1,303 funds tracked by Wall St. Rank hold AMGN as of Q2 2026.

  • Castleview Partners held 10,552 shares of Amgen worth $3.82M as of Q2 2026.
  • Castleview Partners bought 2,692 Amgen shares in Q2 2026, an estimated $922K.
  • Amgen made up 1.68% of Castleview Partners's portfolio in Q2 2026, its #12 holding.
  • Castleview Partners first reported a position in Amgen in Q2 2021 and has held it in 19 quarters since.
  • Castleview Partners's Amgen position peaked at $4.13M in Q4 2025.
  • 1,303 funds tracked by Wall St. Rank held Amgen as of Q2 2026.

Based on Castleview Partners's 13F filing for Q2 2026, filed 20 Jul 2026.